Skip to main content
Equibles

IMRN · Immuron Ltd

Track IMRN — free

Use IMRN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research IMRN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.95 -0.01 (-0.67%)
Rebalance outlook locked
Market Cap
$7.72M
Shares
8.07M
Volume · Oct 20 5010 Avg daily vol (3M) 2.03M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.96 Open$0.95 Day$0.90–0.96 52W close$0.70–2.35 Avg vol 30d280K Short int62K · 0.8% float · 1.0d Short vol28% Last earningsFeb 25, 2026 DataJan 2020–Oct 2026

Up next

Q4 2022 earnings call transcript
Date not confirmed

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
+5.9%
Year over year
Operating margin
-49.9%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+38.0%
Year over year · more shares
Price change (1Y)
-56.7%
Trailing year
Short interest
0.8%
Latest settlement · 1.0 days to cover
View all 122 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Strong Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 18.4 · elevated Equity put/call 0.55
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −6%
below
Price vs 50-day avg −19%
below
RSI (14) 32
neutral
MACD trend Negative
52-week position 16%
mid-range
Momentum
relative strength
Strong
1-month return −23%
trailing
6-month return +16%
trailing
YTD return +25%
this year
Relative strength +8%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow Distributing
-14% holders QoQ · +2 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.77% of float · ▼ -46.6% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
6 holders — mid 3-yr range
Squeeze score 27
low risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 109%
annualized · 1-yr
Max drawdown −70%
past year
ATR 8.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−6% Bearish
Price vs 50-day avg
−19% Bearish
RSI (14)
32 Neutral
MACD trend
Negative Bearish
52-week position
16% Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow Distributing
-14% holders QoQ · +2 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.77% of float · ▼ -46.6% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
6 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $1 · 16% Range high $2
vs 200-day avg -6% vs 50-day avg -19%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
IMRN
Immuron Ltd
this stock
$7.72M +25.3% — — 0.8%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.07B +10.7% +46.2% 29.9 1.8%
MRNA
Moderna, Inc.
 $90.58B +669.4% +4.3% — 7.7%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.51B +1.3% +20.8% 19.4 2.1%
CSLLY
Csl Ltd
 $64.50B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
6
% held
1.0%
Net QoQ
-6.5K sh
Top holder
CITADEL ADVISORS LLC
Held Float
View
Short & Settlement
Short Interest Falling
Shares short
61.8K
Days to cover
1.0d
Change
-53.9K sh
View
Short Volume
Short vol %
28%
As of
Oct 19, 2026
Short Total
View
Fails to Deliver
FTD shares
10.0K
Value
$11.9K
As of
Sep 30, 2026
View
Off-Exchange
Off-exchange %
65.4%
Week of
Sep 14, 2026
Off-exch Lit
View
Filings
SEC Filings
Latest
6-K
Filed
Oct 16, 2026
This year
31

Immuron Limited will ask shareholders on Wednesday, 18 November 2026 to approve a 10% placement facility, renew and expand its Omnibus Incentive Plan, re-elect Dr Jeannette Anne Joughin, and elect Mr Param Lally.

View
Earnings & Events
Webcasts
Last webcast
Sep 21, 2026
View

Performance

5D 20D 120D MTD YTD
IMRN -8.0% -22.9% +16.1% -17.6% +25.4%
SPY -1.5% -0.9% +7.7% +0.5% +12.4%
vs SPY -6.6% -22.0% +8.4% -18.1% +13.0%
Key facts CIK 1660046 CUSIP 45254U101 Visit website Investor relations